All In Biotech

Drug Trial Radar · NCT05806697

Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Apr 14, 2023

Primary completion

Oct 9, 2030

Study completion Oct 9, 2030

Sponsor

Sponsor type
Government (non-federal)
First posted
Apr 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 70 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A regional, single-center, prospective, observational academic cohort will follow subjects who previously participated in the INSIGHT study and who agree an extension of their follow-up in the INSIGHT-2 research for additional 5-6 years. An annual multimodal evaluation (cognitive, oculomotor, biological and neuroimaging) will be proposed in order to describe the natural history of preclinical Alzheimer's disease (AD). The primary endpoint is the conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir positron emission tomography (PET) imaging. The size of the cohort is estimated to around 240 participants (61 A+ subjects) among the 318 participants included in the main cohort (88 A+ subjects). The follow-up in the INSIGHT-2 cohort will be lightened compared to that of the main cohort with an annual frequency of visits rather than a six-monthly one.

Conditions

  • Alzheimer Disease
  • Memory Complaint
  • Memory Disorders

Interventions

  • Electroencephalogram (EEG)Procedure

    The EEG will be uniquely performed during for the whole study if a given subject converts to symptomatic AD or in the occurrence of significant cognitive decline.

  • Oculomotor testsProcedure

    All participants in the INSIGHT-2 study are invited to perform the oculomotor test, excepting subjects reporting oculomotor disorders.

  • MRIProcedure

    All INSIGHT-2 participants will undergo a baseline MRI (structural and resting state fMRI) a follow-up MRI at M12, M36 and M60.

  • 18-F amyloid PET ScanRadiation

    The primary endpoint is conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir PET imaging. Participants will receive an injection of 18F-Florbetapir prior to undergoing amyloid PET scanning. Florbetapir (18F) is an experimental imaging compound labeled with \[18F\] fluorine that decays by positron (β+) emission and has a half-life of 109.77 min. This procedure will be done at baseline.

  • 18F-fluorodeoxyglucose (FDG) PET ScanRadiation

    Participants will receive an injection of Fludeoxyglucose 18F prior to undergoing FDG-PET. The \[18F\]FDG is the most well-known radiopharmaceutical positron emitter, in both clinical and preclinical fields.

  • Blood samplingBiological

    A total of 80 ml of whole blood will be collected for each participant in the INSIGHT-2 study for routine laboratory assessment and biobank sampling.

  • Lumbar punctureBiological

    A lumbar puncture for cerebrospinal fluid (CSF) collection is proposed to all participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint is the conversion to typical AD during the 5-year follow-up.Time frame: every year through study completion, from baseline for 5 years (M60)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hôpital Pitié Salpêtrière

    Paris, Île-de-France Region, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.